Fiche du document
1 avril 2003
- handle: 10670/1.x6g1a1
info:eu-repo/semantics/openAccess
Sujets proches
Soluble ferments Ferments BiocatalystsCiter ce document
Vichai Jirathitikal et al., « Normalization of elevated liver enzymes due to V-1 Immunitor therapy », Electronic Journal of Biotechnology, ID : 10670/1.x6g1a1
Métriques
Partage / Export
Résumé
V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.